Viewing Study NCT05371028


Ignite Creation Date: 2025-12-26 @ 10:32 AM
Ignite Modification Date: 2025-12-31 @ 1:25 PM
Study NCT ID: NCT05371028
Status: COMPLETED
Last Update Posted: 2025-04-06
First Post: 2022-04-28
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada
Sponsor: Takeda
Organization:

Study Overview

Official Title: A Non-interventional, Multicentre Retrospective Study of the Effectiveness and Safety of Teduglutide (REVESTIVE®) in Short Bowel Syndrome Patients in Canada
Status: COMPLETED
Status Verified Date: 2025-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The main aim of this study is to assess the effectiveness and side effects of teduglutide (Revestive®) in real-world clinical practice setting in adult participants with intestinal failure due to short bowel syndrome (SBS-IF) in Canada.

This study is about collecting existing data only; participants receive teduglutide (Revestive®) by their doctors according to the clinical practice but not as part of this study. No new information will be collected during this study.

The study will be conducted using data from the Takeda OnePath Patient Support Program (PSP) or Takeda Global Pharmacovigilance.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
MACS-2020-112501 OTHER Takeda View